Definitive Healthcare (NASDAQ:DH) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Definitive Healthcare (NASDAQ:DH – Free Report) from a hold rating to a buy rating in a report published on Sunday morning.

Other analysts also recently issued research reports about the stock. Bank of America reaffirmed an “underperform” rating and issued a $0.70 price target on shares of Definitive Healthcare in a report on Monday, June 29th. Robert W. Baird set a $1.10 price objective on shares of Definitive Healthcare in a research note on Friday, May 8th. Barclays cut their price objective on Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a research report on Monday, March 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. Finally, Zacks Research upgraded Definitive Healthcare from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have given a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, Definitive Healthcare presently has an average rating of “Reduce” and a consensus price target of $2.47.

Get Our Latest Stock Report on Definitive Healthcare

Definitive Healthcare Trading Up 5.0%

NASDAQ:DH opened at $0.71 on Friday. Definitive Healthcare has a 52-week low of $0.62 and a 52-week high of $4.70. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.81. The stock has a fifty day simple moving average of $0.81 and a 200-day simple moving average of $1.22. The company has a market capitalization of $74.62 million, a PE ratio of -0.44, a price-to-earnings-growth ratio of 10.87 and a beta of 1.33.

Definitive Healthcare (NASDAQ:DH – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. The firm had revenue of $55.93 million for the quarter, compared to analysts’ expectations of $55.02 million. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. On average, equities research analysts expect that Definitive Healthcare will post 0.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds have recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in shares of Definitive Healthcare during the second quarter worth about $32,000. State of Alaska Department of Revenue lifted its stake in shares of Definitive Healthcare by 109.3% during the fourth quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock valued at $32,000 after buying an additional 5,970 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in shares of Definitive Healthcare during the fourth quarter valued at approximately $35,000. Bayesian Capital Management LP acquired a new stake in Definitive Healthcare during the second quarter worth approximately $55,000. Finally, Prelude Capital Management LLC acquired a new stake in Definitive Healthcare during the third quarter worth approximately $64,000. 98.67% of the stock is owned by institutional investors and hedge funds.

Definitive Healthcare Company Profile

(Get Free Report)

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.

Featured Articles